Skip to main content

Systemic Sclerosis: From Pathogenesis Towards Targeted Immunotherapies

Buy Article:

$63.00 plus tax (Refund Policy)

Systemic sclerosis (SSc), a chronic disease with widespread collagen deposition, has three pathogenetic facets: immune activation, microvasculopathy and fibroblast activation. Immune activation and microvasculopathy occur very early in the disease process, and inflammatory infiltrates in the skin are restricted in early-phase disease. There is good evidence that fibroblast activation with collagen production may be triggered by the immune system. In early-phase disease, we slowly move from general immunosuppression to therapeutically targeting specific molecules involved in immune activation, such as T cell-directed targets, B cell-directed targets, cytokine targets, and tyrosine kinases targets.
No References
No Citations
No Supplementary Data
No Data/Media
No Metrics

Keywords: B cell; T cell; fibroblast; immune activation; immunotherapy; systemic sclerosis; targeted therapy

Document Type: Research Article

Publication date: 2012-02-01

More about this publication?
  • Current Rheumatology Reviews publishes frontier reviews on all the latest advances on rheumatology and its related areas e.g. pharmacology, pathogenesis, epidemiology, clinical care, and therapy. The journal's aim is to publish the highest quality review articles dedicated to clinical research in the field.

    The journal is essential reading for all researchers and clinicians in rheumatology.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more